Rankl/Rank/Opg system beyond bone remodeling. Involvement in breast cancer and clinical perspectives by Infante, M. et al.
REVIEW Open Access
RANKL/RANK/OPG system beyond bone
remodeling: involvement in breast cancer
and clinical perspectives
Marco Infante1, Alessandra Fabi2, Francesco Cognetti2, Stefania Gorini3, Massimiliano Caprio3,4† and
Andrea Fabbri1*†
Abstract
RANKL/RANK/OPG system consists of three essential signaling molecules: i) the receptor activator of nuclear factor
(NF)-kB-ligand (RANKL), ii) the receptor activator of NF-kB (RANK), and iii) the soluble decoy receptor osteoprotegerin
(OPG). Although this system is critical for the regulation of osteoclast differentiation/activation and calcium release from
the skeleton, different studies have elucidated its specific role in mammary gland physiology and hormone-driven
epithelial proliferation during pregnancy. Of note, several data suggest that progesterone induces mammary RANKL
expression in mice and humans. In turn, RANKL controls cell proliferation in breast epithelium under physiological
conditions typically associated with higher serum progesterone levels, such as luteal phase of the menstrual cycle and
pregnancy. Hence, RANKL/RANK system can be regarded as a major downstream mediator of progesterone-driven
mammary epithelial cells proliferation, potentially contributing to breast cancer initiation and progression.
Expression of RANKL, RANK, and OPG has been detected in breast cancer cell lines and in human primary breast
cancers. To date, dysregulation of RANKL/RANK/OPG system at the skeletal level has been widely documented in
the context of metastatic bone disease. In fact, RANKL inhibition through the RANKL-blocking human monoclonal
antibody denosumab represents a well-established therapeutic option to prevent skeletal-related events in
metastatic bone disease and adjuvant therapy-induced bone loss in breast cancer. On the other hand, the exact
role of OPG in breast tumorigenesis is still unclear. This review focuses on molecular mechanisms linking RANKL/
RANK/OPG system to mammary tumorigenesis, highlighting pre-clinical and clinical evidence for the potential
efficacy of RANKL inhibition as a prevention strategy and adjuvant therapy in breast cancer settings.
Keywords: RANKL, RANK, OPG, Mammary gland, Breast tumorigenesis, Breast cancer, Metastatic bone disease,
RANKL inhibition, Adjuvant Denosumab
Background
The RANKL/RANK/OPG system was first identified in
the late-1990s as a pivotal regulator of bone remodeling
[1–3]. It consists of three main signaling molecules: the
cytokine receptor activator of nuclear factor (NF)-kB-li-
gand (RANKL; see Table 1 for the list of abbreviations),
the receptor activator of NF-kB (RANK), and the sol-
uble decoy receptor osteoprotegerin (OPG). RANKL,
formerly identified as TRANCE (TNF-related activation-
induced cytokine) [4], is a tumor necrosis factor (TNF)
family member expressed by bone marrow stromal cells,
osteocytes and osteoblasts [3]. RANKL is a homotri-
meric transmembrane protein typically expressed on
osteoblasts and activated T cells, although it can be also
produced as a secretory protein [5]. RANKL binds to
its signaling receptor RANK - a tumor necrosis factor
receptor (TNFR) family member - on the surface of
osteoclast precursor cells, leading to the fusion of these
cells into multinucleated cells which then differentiate
into mature osteoclasts [2, 6, 7]. Mature osteoclasts ad-
here to bone surface and promote bone resorption by
secreting acid and lytic enzymes (e.g. cathepsin K,
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tartrate-resistant acid phosphatase) [2, 8]. OPG is
primarily expressed by bone marrow stromal cells
and osteoblasts, and represents an atypical member
of the TNFR family, since it functions as a soluble
decoy receptor lacking a transmembrane domain [3,
9]. OPG has been found to bind RANKL with ap-
proximately 500-fold higher affinity than RANK [10].
Hence, OPG prevents RANKL from binding to its re-
ceptor RANK, inhibiting osteoclastogenesis and pro-
tecting the bone from excessive osteoclast-mediated
resorption [11, 12].
However, over the last two decades RANKL/RANK
axis has been identified as a critical signaling pathway
involved in several mechanisms beyond bone homeo-
stasis [13]. Specifically, it is essential for different
processes affecting immune regulation, such as inter-
action between T cells and dendritic cells [14],
lymphocyte development, lymph node organogenesis
[15], and thymic development [16]. Furthermore, vari-
ous alternative splicing-derived isoforms of RANKL
and RANK have been detected [17–20], suggesting a
more complex role of RANKL/RANK system than
previously thought. Ikeda et al. identified two add-
itional isoforms of RANKL, namely: i) RANKL 2, with
a shorter intracellular domain than the original form
(RANK 1), and ii) RANKL 3, which lacks a transmem-
brane domain and represents a putative soluble form.
The three isoforms are differentially expressed and
finely regulated in several cell lines (bone marrow
stromal cells, preosteoblastic cells, and various T cells
subsets), suggesting the existence of multiple tissue-
specific pathways with specific roles in osteoclastogen-
esis and T cell differentiation [17].
Intriguingly, RANKL/RANK axis is also required
for hormone-driven mammary gland development
during pregnancy [21]. Given the proliferative effect
of RANKL/RANK signaling on mammary epithelial
cells, several studies suggested a potential involve-
ment of RANKL/RANK system in breast cancer initi-
ation and metastatic progression [22–29]. Conversely,
data on the role of OPG in breast physiology and
tumorigenesis are less univocal and require more in-
vestigations [30–36]. This narrative review is focused
on the emerging roles of RANKL/RANK/OPG system
in mammary gland pathophysiology, highlighting
therapeutic potential of this pathway in human breast
cancer.
RANKL/RANK/OPG system and mammary gland
development
Different studies elucidated the central role of RANKL/
RANK system in mammary gland physiology and
hormone-driven epithelial proliferation during preg-
nancy [3, 21, 22, 37–41]. In mammals, mammary gland
Table 1 List of abbreviations
BRCA1 Breast cancer susceptibility gene 1
BRCA2 Breast cancer susceptibility gene 2
CRAd Conditionally replicating adenovirus
DMBA 7,14-dimethylbenz[a]anthracene
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
EMT Epithelial-mesenchymal transition
ER Estrogen receptor
ErbB Epidermal growth factor receptor
ErbB2 Epidermal growth factor receptor 2
HRT Hormone replacement therapy
Id2 Inhibitor of DNA binding protein 2
IkB Inhibitor of kappa B
IkBα Inhibitor of kappa Bα
IKK-α Inhibitor-kB kinase-α
IgG Immunoglobulin G
IHC methods Immunohistochemical methods
IL-1 Interleukin-1
IL-6 Interleukin-6
IL-8 Interleukin-8
Jak2 Janus kinase 2
LECs Luminal epithelial cells
MaSCs Mammary stem cells
M-CSF Macrophage colony-stimulating factor
MECs Myoepithelial cells
MMTV Mouse mammary tumor virus
MPA Medroxyprogesterone acetate
NF-kB Nuclear factor-kB
OPG Osteoprotegerin
PCR Polymerase chain reaction
PR Progesterone receptor
PRLR Prolactin receptor
PTHrP Parathyroid hormone-related protein
RANK Receptor activator of NF-kB
RANKL Receptor activator of NF-kB-ligand
SREs Skeletal-related events
STAT5a Signal transducer and activator of transcription 5a
TGF-β Transforming growth factor-β
TNBC Triple-negative breast cancer
TNF Tumor necrosis factor
TNFR Tumor necrosis factor receptor
TNFRSF11A TNF Receptor Superfamily Member 11a
TNF-α Tumor necrosis factor-α
TRAF TNF receptor-associated factor
TRAF2 TNF receptor-associated factor-2
TRAIL TNF related apoptosis-inducing ligand
TRANCE TNF-related activation-induced cytokine
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represents a vital organ required to provide maternal
nourishment to newborns in form of calcium-enriched
milk. Therefore, it is likely that during evolution
RANKL/RANK/OPG system - originally required only
for bone remodeling - shifted to calcium-related func-
tions even in mammary gland [21]. The mammary epi-
thelium is made of an inner layer of luminal epithelial
cells (LECs) and an outer layer consisting of myoepithe-
lial cells (MECs) adjacent to a basement membrane that
separates it from the underlying mammary stroma [42].
LECs form the lining of ducts/alveoli and are involved in
milk synthesis and secretion during lactation, whereas
MECs are smooth muscle-like contractile cells facilitat-
ing excretion of milk from the mammary gland [43].
Ductal tree development during sexual maturation and
alveologenesis throughout pregnancy/lactation both re-
quire coordinated morphogenesis and proliferation of
LECs and MECs [39]. In this context, evidence from
murine models supports that RANKL is a key regulator
of mammary epithelial cells proliferation and differenti-
ation, driving the morphogenesis of a lactating mam-
mary gland during pregnancy [21]. Accordingly, RANKL
expression can be induced in murine mammary epithelial
cells after exposure to pregnancy hormones, such as pro-
gesterone, prolactin and parathyroid hormone-related
protein (PTHrP) [21, 44]. This suggests that RANKL is a
major effector of hormone-driven mammary epithelium
response during early pregnancy [21]. In fact, RANKL is
absent in virgin mammary glands, but its expression pro-
gressively increases in LECs between the 17th and 26th
day of the menstrual cycle [21], and throughout pregnancy
[38]. On the other hand, RANK is present at low levels in
both luminal and basal mammary epithelial cells, but its
expression is higher at mid-gestation (especially at the
level of ductal branch points) [45]. Genetic studies docu-
mented that both RANKL and progesterone receptor (PR)
are localized in LECs, acting on similar stages of the mam-
mary gland morphogenesis [44]. Notably, progesterone
has mitogenic effects on mammary epithelial cells through
two distinct waves of proliferation. The first wave affects
PR-positive cells and requires cyclin D1, while a second
larger wave encompasses PR-negative cells and relies on
RANKL. In particular, progesterone upregulates RANKL
expression on PR-positive LECs. In turn, RANKL drives
proliferation of neighboring estrogen receptor (ER)/
PR-negative LECs, acting in a paracrine fashion via its re-
ceptor RANK [23, 40, 46] (see Fig. 1a). Indeed, mice lack-
ing PR-B isoform show defects of ductal side-branching
and lobulo-alveologenesis during pregnancy, along with
impaired RANKL expression [47]. Conversely, ectopic ex-
pression of RANKL completely blunts defects of
PR-deficient cells in the morphogenesis of lactating mam-
mary gland, supporting a crucial role of RANKL in medi-
ating progesterone-driven mitogenic effects on mammary
epithelial cells [40, 41]. Moreover, it has been found that
RANKL is able to increase proliferation of MECs in cul-
tured mammary organoids obtained from adult mice [39]
(Fig. 1a). Similar to progesterone, prolactin is also neces-
sary for a proper development of mammary gland during
pregnancy. Specifically, prolactin acts through Jak2/
STAT5a signaling in order to induce RANKL expression
by mammary epithelial cells [38]. Altogether, these find-
ings highlight the existence of a strict relationship between
progesterone, prolactin and RANKL/RANK system in
driving the morphological changes of mammary gland
during pregnancy.
At a molecular level, RANKL binds RANK - constitu-
tively expressed on the surface of basal and luminal
mammary epithelial cells - and regulates proliferation of
mammary epithelial cells. RANKL/RANK axis functions
through two different downstream signaling pathways:
1) the first pathway triggers activation of inhibitor-kB
kinase(IKK)-α, resulting in proteasome degradation of
IkBα (inhibitor of kappa Bα) and its dissociation from
NF-kB, which migrates to the nucleus and induces cyclin
D1 transcription [48–50]; 2) the second pathway pro-
motes nuclear translocation of the transcriptional regu-
lator inhibitor of DNA binding protein 2 (Id2), which
subsequently downregulates cell cycle inhibitor p21 [51]
(see Fig. 1b). These molecular pathways provide survival
and proliferative signals required for development of
lobulo-alveolar structures during the course of preg-
nancy [48, 52]. Accordingly, RANKL and RANK null
mice exhibit normal mammary fat pad development dur-
ing puberty, but they show impaired lobulo-alveolar
morphogenesis during pregnancy and lactational defect
at parturition due to increased apoptosis and defective
proliferation of mammary epithelium [21]. In agreement
with these findings, female mutant mice lacking PR, pro-
lactin receptor (PRLR), IKK-α, Id2, or STAT5a display
similar phenotypes to those observed in RANKL or
RANK-deficient mice [47, 48, 53–55]. Conversely, trans-
genic mice overexpressing RANKL or RANK show in-
creased proliferation of mammary epithelium, with
precocious ductal-side branching and alveolar budding
[45, 54]. Importantly, RANKL/RANK axis is also
involved in mammary stem cell biology [56, 57]. RANKL
has been identified as a paracrine effector of
progesterone-driven expansion of adult mammary stem
cells (MaSCs) observed during pregnancy and luteal
phase of the menstrual cycle. MaSCs reside in the basal
compartment of mammary epithelium and have the abil-
ity of self-renewal and multipotency. In fact, MaSCs can
differentiate into all mammary cell lineages (ductal and
alveolar LECs, as well as ductal and alveolar MECs), be-
ing able to regenerate the entire mammary epithelial tree
[58, 59]. Although MaSCs lack both ER and PR, they are
highly responsive to steroid hormone signaling, as
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supported by the fact that MaSCs pool increases during
the luteal diestrus phase and throughout pregnancy [56,
57]. Progesterone promotes selective upregulation of
RANKL and RANK on breast luminal and MaSC-
enriched basal cells, respectively. RANKL from LECs
binds to its cognate receptor RANK on basal cells, fur-
ther upregulating RANK expression and activating
RANK downstream signaling pathways that promote
MaSCs proliferation and expansion [56, 57, 60] (Fig.
1a). Accordingly, Joshi et al. examined murine models
treated with a RANKL inhibitor, documenting that loss
of RANK signaling blunts the progesterone-induced
proliferation of hormone receptor-negative murine
mammary progenitors [61]. Moreover, whole-body anti-
RANKL treatment of virgin and pregnant mice signifi-
cantly impairs the clonogenicity of MaSC-enriched
basal cell population in vitro [56]. In addition, selective
genetic ablation of RANK in the basal compartment of
mammary epithelium leads to defective lobulo-alveolar
development and lactation [25], while no defect is ob-
served when RANK deletion occurs in luminal cells
[62]. These findings highly suggest that RANK signaling
is crucial in basal cells - but not in luminal cells - for
the development of lactating mammary tissue, and
RANKL/RANK axis promotes progesterone-induced
MaSCs expansion in a paracrine fashion during the
luteal phase of the menstrual cycle and throughout
pregnancy.
In order to assess whether RANKL plays all the
aforementioned physiological roles also in humans,
Tanos et al. developed an ex vivo model consisting of
tissue microstructures isolated from fresh human
breast tissue specimens of healthy donors [63]. Of
note, PR signaling has been shown to promote LECs
proliferation by induction of the same mediators of
progesterone action identified in murine models,
namely Wnt-4 and RANKL [40, 63, 64]. Specifically,
progesterone controls RANKL mRNA levels predom-
inantly by post-transcriptional mechanisms (increased
mRNA maturation/stability) [63]. RANKL protein ex-
pression is also positively associated with serum pro-
gesterone concentrations in the human breast in vivo
[63]. Accordingly, Azim et al. found that pregnancy
increases RANKL expression both in normal human
Fig. 1 Schematic diagram showing PR/RANKL pathway and downstream RANK-mediated signaling in mammary epithelial cells. a Natural or
synthetic progesterone binds to its receptor in PR-positive breast luminal cell, leading to an increase in RANKL protein levels mainly through
stabilization of its mRNA. Then, RANKL binds to its cognate receptor RANK expressed on the surface of the neighboring PR-negative breast
luminal cell, activating downstream signaling pathways that promote cell proliferation. Basal cells (MECs and MaSCs, drawn in green at the
bottom of the figure) constitutively express RANK on their surface, but they lack PR. RANKL produced by PR-positive breast luminal cells further up-
regulates RANK expression on MECs and MaSCs surface, and activates RANK-downstream signaling pathways promoting cell proliferation, expansion
and survival. b RANK-IKK-α-NF-kB-cyclin D1 pathway (1), and RANK-Id2-p21 pathway (2) represent the two main signaling pathways activated by RANK
in mammary epithelial cells. IKK-α catalyzes phosphorylation, ubiquitination and proteasome degradation of IkBα, leading to its dissociation
from NF-kB, which then migrates to the nucleus and induces cyclin D1 transcription. On the other hand, Id2 translocates into the nucleus and
reduces expression of the cell cycle inhibitor p21. Altogether, these molecular events result in increased proliferation and survival of mammary
epithelial cells. RANK-c is a RANK isoform derived from alternative splicing of RANK gene, which has been identified in breast cancer cell lines
and breast tumors. It acts as a dominant negative regulator of RANK-dependent NF-kB activation, inhibiting the NF-kB-mediated cell survival
effect and correlating with lower cell motility and proliferative index. RANK-c may exert its function through the intracellular interaction with
other key molecules, such as TRAF2 and EGFR. Notably, RANK-c has also been shown to act as a negative regulator of EGFR signaling, inhibiting EGFR
phosphorylation after EGF ligand stimulation. Abbreviations: EGF, Epidermal growth factor; EGFR, Epidermal growth factor receptor; Id2, inhibitor of
DNA binding protein 2; IkBα, inhibitor of kappa Bα; IKK-α, inhibitor-kB kinase-α; LECs, luminal epithelial cells; MaSCs, mammary stem cells;
MECs, myoepithelial cells; NF-kB, nuclear factor-kB; Pg, natural or synthetic progesterone; PR, progesterone receptor; RANK, receptor activator
of NF-kB; RANKL, receptor activator of NF-kB-ligand; TRAF2, TNF receptor-associated factor-2
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breast and primary breast tumors [65]. These data
suggest that progesterone-induced RANKL expression
may represent a conserved hormonal pathway in mice
and humans, able to control cell proliferation in breast
epithelium under physiological conditions commonly
associated with higher serum progesterone levels (e.g.
luteal phase of the menstrual cycle, pregnancy).
On the other hand, data on the exact role of OPG in
mammary gland physiology are not univocal. Even
though OPG mRNA is expressed in normal breast tissue
and its transcription is regulated by pregnancy hormones
(especially estrogen) [66], there is scarce evidence for a
direct role of OPG in breast development and function
[30]. In fact, neither female OPG-overexpressing trans-
genic mice nor OPG-deficient mice show any impair-
ment in mammary gland formation [32, 33]. On the
other hand, Vidal et al. detected 1000-fold higher con-
centrations of OPG in human milk than in serum, sug-
gesting a possible role of OPG in mammary gland
development during lactation. The same study showed
that both human breast milk cells and human mammary
epithelial cell line MCF-7 express OPG [34]. However,
these findings still do not demonstrate an essential role
of OPG in breast development and pregnancy-related
mammary gland morphogenesis, and studies elucidating
the role of OPG in breast physiology are awaited.
Role of RANKL/RANK system in breast
tumorigenesis
Breast cancer represents the most common female can-
cer, accounting for around 25% of all cancers [67]. Risk
factors for breast cancer include age over 40, genetic
predisposition, Caucasian race, early menarche, late
menopause, late childbearing, hormonal contraception,
and hormone replacement therapy (HRT) [68]. Proges-
terone and its synthetic derivatives (progestins) are
commonly used in combined HRT (estrogen plus pro-
gesterone) and hormonal contraception [69, 70]. The
Women’s Health Initiative and the Million Women
Study provided evidence that women using combined
HRT show a significant increase in risk of incident and
fatal breast cancer, compared with women using estro-
gen alone [71–73]. Other studies documented that risk
for breast cancer development is associated with men-
strual cycles and related peaks in serum progesterone
levels [74]. Overall, progesterone and progestins are con-
sidered key factors for increased breast cancer risk in
women. Several pre-clinical studies demonstrated that
RANKL/RANK system promotes breast tumorigenesis
[23, 24, 26, 27, 46], suggesting that such system may ac-
count, at least in part, for the increased incidence of
breast cancer associated with use of progesterone and
progestins. As previously mentioned, progesterone is a
powerful driver of RANKL expression, which in turn
induces proliferation of mammary epithelial and stem
cells both in mice and humans [40, 46, 63, 75]. Intri-
guingly, breast tumorigenesis is sustained through the
same pathway. First, the expression of RANKL and
RANK has been documented in breast cancer cell lines
and in human breast cancers [23, 24, 76–78]. Moreover,
RANK expression in tumor tissue has been significantly
associated with poor disease-free survival in primary hu-
man breast cancer [78]. A growing body of evidence in-
dicates that RANKL/RANK axis is a crucial mediator of
the proliferative changes observed in mammary epithe-
lium during the onset of primary progesterone-driven
breast cancer [23, 25, 79]. Schramek et al. showed that
female mice treated with the progestin medroxyproges-
terone acetate (MPA) exhibit a massive upregulation of
RANKL expression in mammary epithelial cells, result-
ing in a rapid and marked cell proliferation that is in-
stead significantly decreased in RANK deficient mice
[25]. Given that MPA-induced tumorigenesis requires a
carcinogen [80], the authors used the DNA-damaging
agent 7,14-dimethylbenz[a]anthracene (DMBA) in com-
bination with MPA to promote DNA mutations and
mammary cancer development [25]. Surprisingly,
RANK-deficient mice showed a remarkable delay in the
onset of MPA/DMBA-induced mammary cancer, as well
as an enhanced survival when compared with the
wild-type controls. Similarly, IKK-α knockout mice ex-
hibited a delayed onset of mammary tumors after MPA/
DMBA treatment, indicating that RANKL/RANK system
acts through IKK-α pathway even in hormone-driven
mammary tumorigenesis [25]. Another study reported
that transgenic mice with a gain of function of RANK
display an increased susceptibility to development of
pre-neoplastic mammary lesions and mammary tumors
(adenocarcinoma, adenosquamous carcinoma and adeno-
myoepithelioma carcinoma histotypes) following MPA/
DMBA treatment [23]. On the contrary, use of the select-
ive pharmacological RANKL inhibitor RANK-Fc reduces
mammary epithelial proliferation and attenuates the oc-
currence of pre-neoplastic lesions and mammary tumors
in RANK-transgenic mice and wild-type controls [23].
Transgenic mice overexpressing epidermal growth factor
receptor 2 (ErbB2) under the transcriptional control of
the mouse mammary tumor virus (MMTV) promoter
represent a spontaneous mammary tumor model, which
does not require any hormonal exposure for tumorigen-
esis [81]. Interestingly, RANK-Fc displays anti-tumoral ef-
fects even in MMTV-ErbB2 transgenic mice [23].
RANKL and RANK can be both expressed in triple-
negative breast cancer (TNBC) [82]. Interestingly, dual
expression of RANKL and RANK correlates with a poor
prognosis in TNBC patients. In fact, TNBC patients ex-
pressing both RANKL and RANK show significantly
worse relapse-free survival and overall survival than
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patients with RANKL-negative RANK-positive TNBCs
[82]. These data suggest that RANKL could contribute
to spontaneous formation of breast cancer even through
hormone-independent mechanisms. Indeed, the pres-
ence of RANKL within human mammary tumor epithe-
lium and tumor stroma (e.g. mononuclear cells,
fibroblast-like stromal cells) indicates that its activation
in breast cancer may be also regulated by mechanisms dif-
ferent from those mediated by progesterone and proges-
tins [23, 76]. Moreover, RANK signaling may promote
breast cancer development even through mechanisms
other than the well-established induction of cell prolifera-
tion. In fact, RANKL/RANK axis favors cell survival pro-
tecting DNA-damaged mammary epithelial cells from
apoptosis, and controls anchorage-independent growth
and self-renewal capacity of tumor-initiating cells [25].
RANKL/RANK system is also involved in epithelial-
mesenchymal transition (EMT) [83], which is one of the
initial steps in carcinogenesis that promotes the acquisi-
tion of stem-like properties and malignant features by
epithelial cells (e.g. loss of cell-cell adhesion, enhanced
migratory capacity, increased invasive potential, aug-
mented extracellular matrix components, and resistance
to apoptosis) [26, 84, 85]. Tsubaki et al. demonstrated
that RANKL induces EMT in RANK-expressing normal
mammary epithelial cells and breast cancer cells through
NF-kB activation and upregulation of Snail and Twist,
two transcriptional repressors of the epithelial marker
E-cadherin. These molecular events lead to downregula-
tion of E-cadherin and upregulation of mesenchymal
markers (e.g. N-cadherin and vimentin), which result in
tumor cell migration, invasion and metastasis [26]. Fur-
thermore, there is evidence supporting a potential role
of immune system in driving the pro-metastatic behavior
of breast cancer cells [86]. Regarding this context, Tan et
al. found that RANKL produced by tumor-infiltrating
regulatory T cells elicits metastatic spread of mammary
cancer cells via RANK signaling [27].
Noteworthy, several studies identified novel RANK
isoforms generated through alternative splicing of the
RANK gene (TNFRSF11A: TNF Receptor Superfamily
Member 11a), further increasing the functional complex-
ity of RANKL/RANK system in normal and tumor cells
[18–20, 87]. Importantly, these isoforms play an import-
ant role in the regulation of RANK downstream signal-
ling, mitigating the wild type RANK-mediated
promotion of breast cancer initiation, progression and
metastasis [18–20]. The RANK isoform RANK-c, which
lacks the transmembrane domain and a large portion of
the intracellular part of the wild type receptor RANK,
has been first detected in breast cancer cells and breast
tumors by Papanastasiou et al. [18, 19]. Intriguingly, the
authors showed that RANK-c acts as a dominant nega-
tive regulator of RANK-dependent NF-kB activation,
inhibiting RANK translocation to the cell membrane
and the NF-kB-mediated cell survival effect (Fig. 1b).
RANK-c expressing breast cancer cells also exhibited
lower cell motility and migration rates, indicating a pu-
tative role of RANK-c isoform in cytoskeleton remodel-
ing. Moreover, RANK-c expression was found inversely
correlated with tumor histological grade and prolifera-
tive index, further suggesting a possible role of this iso-
form as a suppressor of breast cancer progression and
metastasis [18, 19]. Sirinian et al. reported that RANK-c
is expressed in 3.2% of cases among The Cancer Gen-
ome Atlas breast cancer cohort, and its expression is
evenly distributed across ER-negative and ER-positive
cases. Nonetheless, ER-negative breast cancer cell lines
showed an increased RANK/RANK-c ratio compared to
ER-positive counterparts. Intriguingly, forced expression
of RANK-c in ER-negative breast cancer cell lines was
able to counteract NF-kB activation, suppressing aggres-
sive cell properties (e.g. migration, invasion, and
colony-forming ability). RANK-c exhibited similar prop-
erties in vivo, preventing lung metastases of MDA-
MB-231 cells in mice. Moreover, analysis of RANK-c
transcript levels from primary breast cancer samples
showed that RANK-c expression positively correlates
with less aggressive disease, as assessed by the absence
of distant metastases at the time of diagnosis. At a mo-
lecular level, the authors provided evidence that the
RANK-c-mediated inhibition of NF-kB activation relies
on the interaction with other key molecules, such as TNF
receptor-associated factor-2 (TRAF2) and epidermal
growth factor receptor (EGFR) [20]. TNF receptor-associ-
ated factor (TRAF) proteins are major components of
RANK receptor signalling [88, 89]. In presence of
RANK-c, TRAF2 preferentially binds to this isoform, ex-
cluding RANK from the protein complex. Furthermore,
RANK-c has also been shown to act as a negative regula-
tor of EGFR signalling. In fact, RANK-c expressing cells
showed impaired EGFR phosphorylation after epidermal
growth factor (EGF) ligand stimulation, resulting in inabil-
ity to activate critical downstream signalling mediators
[20] (Fig. 1b). Overall, these data suggest a potential role
of RANK-c as a prognostic biomarker in breast cancer, as-
sociated with disease severity and metastasis. Neverthe-
less, clinical studies are needed in order to translate these
findings in clinical settings.
A possible correlation between RANK pathway and
some members of the human epidermal growth factor
receptor (ErbB) family has also been documented [23,
27, 90, 91]. ErbB family consists of four different type I
transmembrane growth factor receptor tyrosine kinases
(EGFR, HER2, HER3, and HER4), which activate down-
stream intracellular signaling pathways involved in nor-
mal cell development, as well as in human cancer [92,
93]. In fact, EGFR and other members of the ErbB
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family are often co-expressed in several cancers, con-
tributing to increased cell proliferation and aggressive-
ness, as well as drug resistance [94–96]. Yi et al. first
showed the existence of a strict interaction between
RANKL/RANK system and EGFR pathway during osteo-
clastogenesis, showing that RANKL up-regulates EGFR
expression in differentiating osteoclasts. Moreover, inhib-
ition of EGFR blunted the activation of RANKL/RANK
signaling pathway and RANKL-dependent osteoclast for-
mation in osteoclast precursor cells, and led to caspase-
mediated apoptosis in differentiated osteoclasts [97].
These data highly suggest that EGFR signaling plays a crit-
ical role in osteoclast differentiation and survival. Consist-
ent with these findings, RANKL inhibition has been
shown to enhance the antineoplastic effects of panitumu-
mab (a fully human anti-EGFR monoclonal antibody) in a
murine model of bone metastasis, where it prevented
tumor-induced osteolysis and led to a greater reduction in
skeletal tumor growth compared to panitumumab alone
[98]. Papanastasiou et al. provided evidence of a molecular
interaction between RANK and EGFR pathways in pri-
mary breast cancer. The authors showed a significant
positive correlation between RANK mRNA and EGFR
gene and protein expression in invasive breast cancer
samples and breast cancer cell lines, whereas no correl-
ation between RANK and the other ErbB family members
was found. Interestingly, breast cancer cells co-expressing
RANK and EGFR exhibited a significant enhancement of
the EGFR downstream signaling and a higher invasive po-
tential, supporting a synergistic effect of RANK and EGFR
at both molecular and cellular level. Moreover, the sub-
group of “double positive” breast cancer patients (RAN-
Khi/EGFRhi) displayed a worse clinical outcome, consisting
of a reduced overall survival independently of tumor stage
and primary lymph node [90]. Different studies also docu-
mented the involvement of RANK pathway in ErbB2-posi-
tive breast carcinogenesis [23, 27, 91]. ErbB2 (or HER2) is
a member of the ErbB receptor tyrosine kinase family; its
overexpression is observed in approximately 20% of hu-
man breast cancers and correlates with poor prognosis
[91]. Indeed, activation of NF-kB - the major downstream
mediator of RANK signaling - has been associated with
cell survival, proliferation, and invasion, as well as resist-
ance to anti-ErbB2 agents in ErbB2-positive breast cancers
[91, 99, 100]. Pharmacological inhibition of RANKL has
been shown to decrease spontaneous mammary tumori-
genesis, proliferation and metastatic potential in
MMTV-ErbB2 transgenic mice [23]. In another study,
MMTV-ErbB2/Rank+/− mice exhibit a remarkable reduc-
tion of metastatic rates compared to MMTV-ErbB2/
Rank+/+ group [27]. Moreover, the NF-kB-activating pro-
tein IKK-α supports ErbB2-induced tumor initiating cells
expansion promoting nuclear export of p27, a negative
regulator of the G1/S phase transition [101]. Then, NF-kB
activity enhances ErbB2-mediated murine mammary
tumorigenesis by stimulating tumor angiogenesis [102].
Interestingly, anti-ErbB2 agents can even elicit NF-kB
activation, enhancing the oncogene addiction of ErbB2-
positive cells to NF-kB [103]. The latter mechanism could
provide a rationale for the development of resistance to
anti-ErbB2 drugs in ErbB2-positive breast cancer patients
[100]. Therefore, the combination of anti-ErbB2 drugs
with NF-kB inhibitors [100] or proteasome inhibitors -
which prevent NF-kB activation through inhibition of IkB
degradation [103] - may represent a novel and more valu-
able therapeutic approach to treat RANK-expressing
ErbB2-positive breast cancers.
Overall, these data strongly encourage further investi-
gation on the potential use of a double pathway inhib-
ition strategy in the subgroup of “double positive”
breast cancer patients (RANK-positive and EGFR- and/
or ErbB2-positive) through the existing molecules tar-
geting RANKL/RANK pathway and ErbB family mem-
bers (e.g. denosumab plus anti-EGFR drugs, such as
erlotinib or panitumumab; or denosumab plus anti-
ErbB2 drugs, such as lapatinib or trastuzumab). Hence,
future clinical trials are awaited to assess whether this
double inhibition approach may lead to significant
advantages.
Role of RANKL/RANK system in BRCA1 mutation-driven
breast tumorigenesis
Approximately 5–10% of breast cancers are hereditary
and the vast majority of them are due to germline mu-
tations in BRCA1 and BRCA2 tumor suppressor genes
[104–106]. BRCA1 and BRCA2 encode proteins that
cooperate to protect the genome from DNA damage
during DNA replication; therefore, loss of these genes
causes defective repair of damaged DNA, leading to
chromosomal instability and increased cancer suscepti-
bility among mutation carrier patients [107]. Several
pre-clinical studies have documented that female sex
hormones play an important role in the pathogenesis of
BRCA1-mediated mammary tumorigenesis. Specifically,
BRCA1 is involved in the regulation of both ER and
PR, inhibiting the expression of various endogenous es-
trogen- and progesterone-responsive genes [108–110].
Indeed, progesterone antagonist mifepristone prevents
mammary tumorigenesis in BRCA1/p53-deficient mice
[111] and prophylactic salpingo-oophorectomy mark-
edly decreases the risk of developing breast cancer in
women with BRCA1 mutation [112]. Moreover, it has
been shown that luteal phase-related levels of estrogen
and progesterone are significantly higher in BRCA1
mutation carriers compared with women not carrying
mutation [113]. Given the established role of female sex
hormones in the pathogenesis of BRCA1 mutation-driven
breast cancer, different studies investigated whether
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RANKL/RANK axis could act as a downstream mediator
of sex hormones in breast tumorigenesis of BRCA1 muta-
tion carriers [28, 29, 79]. With this regard, Sigl et al. docu-
mented that genetic ablation of RANK in basal mammary
epithelial cells of mice carrying a BRCA1;p53 mutation
significantly decreases proliferation and markedly abro-
gates the occurrence of intraepithelial neoplasms and in-
vasive carcinomas [28]. Pharmacological inhibition of
RANKL has been found to reduce the development of
BRCA1 mutation-driven pre-neoplastic mammary lesions
in mice carrying BRCA1 mutation. Intriguingly, the hu-
man monoclonal antibody denosumab significantly re-
duces in vitro colony-forming capacity of mammary
epithelial progenitor cells from women carrying heterozy-
gous germline BRCA1 mutations who underwent prophy-
lactic mastectomy. These findings indicate that RANKL/
RANK system strictly controls the expansion of BRCA1--
mutated human mammary progenitor cells. Furthermore,
authors identified six single-nucleotide polymorphisms in
the locus encoding for human RANK (TNFRSF11A), that
are significantly associated with breast cancer risk in a
wide series of BRCA1 mutation carriers. Finally, it has
also been found that RANKL and RANK are highly
expressed in pre-malignant lesions, as well as in breast
cancer samples from both BRCA1 and BRCA2 human
mutation carriers [28]. Consistent with these data, Nolan
et al. identified RANK-positive and RANK-negative cells
as two distinct subsets of luminal progenitor cells from
histologically normal breast tissue of BRCA1 mutation
carriers, demonstrating that RANK-positive progenitors
are highly proliferative and more prone to DNA damage.
Notably, progesterone-induced proliferation of three-di-
mensional breast organoids derived from breast biopsies
of women carrying BRCA1 mutation is markedly reduced
after exposure to denosumab. Proliferation of mammary
epithelial cells - assessed by Ki67 expression - is also sig-
nificantly reduced in breast biopsies from three BRCA1
mutation carriers treated with denosumab [29]. Taken to-
gether, these data indicate that progesterone-induced
RANKL may critically affect BRCA1-mutation driven
breast tumorigenesis by promoting the expansion of
RANK-positive murine and human mammary progenitor
cells, which therefore represent a crucial target cell popu-
lation in BRCA1 mutation carriers.
Pitfalls and controversies in detection of RANKL/RANK
expression and distribution
In light of the above mentioned findings, RANKL and
RANK represent interacting molecules considered as
potential therapeutic target in different neoplastic and
non-neoplastic diseases. Therefore, their expression
and distribution in normal and diseased human tissues
are of critical interest in relation to safety and efficacy of
drugs targeting the RANKL/RANK pathway. However,
immunohistochemical (IHC) methods using a variety of
antibodies have shown inconsistencies between the find-
ings comparing the distribution of RANKL and RANK in
different tissues, including breast tissue [65, 75, 114, 115].
It is also important to remark that RANKL and RANK ex-
pression may vary under different physiological conditions
[116], such as the menstrual cycle [75] or the immune re-
sponse [116, 117]. Nonetheless, it is possible to make
some general reflections. In adult tissues, RANKL distri-
bution is more strictly limited to bone (activated osteo-
blasts), as well as to spleen, peripheral lymph nodes and
mammary epithelium [9, 21, 118]. On the other hand,
RANK expression occurs in several tissues and is more
dependent upon various tissue-specific regulating factors,
including progesterone and PTHrP within the mammary
epithelium [21, 116–120]. Moreover, reports of the broad
RANK protein and mRNA distribution are not consistent
with the limited functional role of RANKL/RANK path-
way [117], thus highlighting the need for sensitive and
specific tools able to detect RANKL and RANK protein
expression in both normal and pathologic tissues. This
matter is of crucial importance especially for clinical trials
evaluating the possible correlation of RANKL and/or
RANK tumor expression with clinical outcomes. Indeed,
Taylor et al. reported that RANKL detection with IHC
methods is relatively straightforward, whereas RANK is a
“difficult to detect antigen”. In particular, the ability of
IHC methods to detect RANK protein in formalin-fixed
paraffin-embedded tissues may be negatively affected by
conditions of sample preparation and/or different IHC
techniques (e.g. time of fixation, epitope retrieval pro-
cesses, degree of amplification, different specificity and
sensitivity features of the primary antibodies), which are
assumed to vary across different laboratories. Indeed, the
authors proposed an optimized IHC protocol using
well-characterized and highly specific antibodies to prop-
erly detect the expression patterns of RANKL and RANK
in normal and pathologic tissues and to develop a repro-
ducible assay that could be transferred and compared be-
tween laboratories [114]. These observations have a major
impact in all studies evaluating the expression of RANKL
and/or RANK in human tissues, highlighting that a
non-rigorous choice of antibodies or the use of
non-validated IHC protocols may lead to misleading find-
ings in RANKL and, particularly, RANK expression.
Role of OPG in breast tumorigenesis
In skeletal metastases, RANKL/OPG ratio is often
increased, with an upregulation of RANKL and a
concomitant downregulation of OPG, resulting in
osteoclast-mediated bone destruction [44]. Since OPG
is a negative regulator of osteoclast maturation and
bone resorption [32], early studies focused on the po-
tential use of recombinant OPG to prevent osteolysis
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related to bone metastasis in breast cancer. Truncated
forms of recombinant OPG have been developed, con-
sisting of the N-terminal part of the protein - essential
for interaction with RANKL - fused to the Fc domain
of human IgG. Interestingly, recombinant OPG has
been shown to completely prevent osteolytic metastatic
lesions caused by MDA-MB-231 human breast cancer
cells in nude and ovariectomized mice [121, 122]. A
phase I study demonstrated that the recombinant OPG
construct AMGN-0007 leads to a sustained decrease in
serum markers of bone resorption when administered
to breast cancer patients [123], although development
of the compound has been then discontinued due to
potential safety risks deriving from an immune re-
sponse against endogenous OPG [117]. However, other
studies showed a more complex role of OPG in breast
tumorigenesis [31, 35, 36, 124–127]. In fact, Tan et al.
first documented OPG expression in two human breast
cancer cell lines, namely MCF-7 and MDA-MB-436
[128]. The expression pattern of OPG has also been
assessed by immunohistochemistry in approximately
400 invasive human breast cancer tissue samples: 40%
of these tumors showed a strong immunohistochemical
OPG expression, which was selectively confined to the
tumor cells [35]. A study conducted on 185 patients
with primary breast cancer found OPG expression in
approximately 46% of cases [78]. Furthermore, OPG ex-
pression positively correlates with the presence of ER
and PR in human breast tumor samples [76]. Neverthe-
less, 17beta-estradiol has been shown to suppress OPG
production by human ER-positive breast cancer cell
lines in a dose-dependent manner [129]. Therefore, the
effects of ER activation on OPG expression in breast
cancer cells may be different from those observed at
the skeletal level under physiological conditions [130].
Given that OPG is not required for normal mammary
gland development and lactation [33], its expression
may represent a novel mechanism through which tumor
cells gain a growth advantage by different molecular
mechanisms [31]. In fact, it has been reported that OPG
can bind and inhibit TNF related apoptosis-inducing lig-
and (TRAIL) [131]. TRAIL is a member of the TNF family
produced in cancers by invading monocytes, and acts as
an inducer of apoptosis in tumor cells upon binding to its
death domain-containing cell surface receptors [132]
(Fig. 2). Holen et al. showed that OPG can act as an endo-
crine survival factor in MDA-MB-436 and MDA-MB-231
breast cancer cells by substantially reducing the extent of
TRAIL-induced apoptosis [35]. Thus, breast cancer cells
could use OPG secretion to gain a survival advantage over
the host defenses. However, the relevance of OPG-TRAIL
interaction in the context of breast cancer still awaits
demonstration in vivo. In fact, it has been shown that
MDA-MB-231 human breast cancer cells overexpress-
ing full length OPG display decreased sensitivity to
TRAIL-induced apoptosis in vitro, whereas there is a
Fig. 2 Schematic illustration of main OPG sources and actions in breast tumorigenesis. According to most pre-clinical findings, OPG produced by
breast cancer and endothelial cells is able to promote tumor growth at the primary tumor site, as well as development of metastatic tumors at
extra-skeletal sites, through distinct mechanisms: a inhibition of the monocyte-derived apoptosis inducing factor TRAIL, b increased expression of
some proteases (e.g. cathepsin D, matrix metalloproteinase-2), c induction of endothelial cells proliferation and differentiation to form new blood
vessels (angiogenesis). Conversely, OPG produced in bone microenvironment can mitigate intra-osseous tumor growth and prevent breast cancer-
induced osteolysis by reducing differentiation and activation of mature osteoclasts lining the bone surface. Abbreviations: OPG, osteoprotegerin; TRAIL,
TNF related apoptosis-inducing ligand. Adapted from Weichhaus et al., Mol Cancer (ref. [31])
Infante et al. Journal of Experimental & Clinical Cancer Research           (2019) 38:12 Page 9 of 18
lack of effect in vivo despite the presence of OPG at
supraphysiological concentrations [36]. The role of
breast cancer cells-derived OPG could be more com-
plex in vivo due to the simultaneous presence of
RANKL and TRAIL. Although OPG binds RANKL and
TRAIL with the same affinity in vitro [133], the
addition of excess RANKL is able to reverse the effect
of OPG on TRAIL-mediated apoptosis in human breast
cancer cells [125]. Similarly, high levels of RANKL
present at a skeletal level - especially in the context of
metastatic bone disease [44] - may explain why OPG
protects bone microenvironment from breast cancer-
induced osteolysis and mitigates intra-osseous tumor
growth, whereas it is able to promote primary tumor
growth and cancer cells spread to sites out of the bone
[134]. However, the strict interactions between TRAIL,
OPG, and RANKL in the context of the primary breast
tumor still need to be elucidated in vivo. Apart from
direct proliferative actions of OPG on breast cancer
cells, several studies reported additional mechanisms
whereby OPG may exert its tumor-promoting effect in
breast cancer. For instance, Cross et al. documented a
positive association between endothelial OPG expres-
sion and high tumor grade in breast cancers, support-
ing a potential role of OPG as a pro-angiogenic factor
in breast tumor microenvironment [126]. Goswami et
al. investigated an in vitro model of angiogenesis, pro-
viding evidence for a role of OPG in driving neoangio-
genesis in endothelial tube formation [127]. Hence, it is
likely that OPG produced either by breast tumor cells
or endothelial cells themselves promotes endothelial
cell survival and differentiation, inducing angiogenesis
and stimulating primary tumor growth [124]. OPG has
also been shown to reprogram normal mammary epi-
thelial cells to a tumorigenic state through induction of
proliferation and aneuploidy [127]. In addition, Weich-
haus et al. demonstrated that OPG stimulates breast
cancer cells invasion and metastasis by modulating ex-
pression of the proteases Cathepsin D and Matrix
Metalloproteinase-2 [135] (Fig. 2). In the same study,
the authors also showed that knockdown of OPG in
TNBC cells leads to a significant reduction in metasta-
sis in the chick embryo metastasis model [135]. Inter-
estingly, Owen et al. analyzed OPG expression in 127
primary human breast cancer tissues, finding that pa-
tients with higher expression of OPG in tumor samples
show a significantly poorer overall survival with respect
to patients with lower OPG expression [136]. Sarink et
al. have recently conducted a large-scale prospective
study on 2006 pre- and postmenopausal patients with
incident invasive breast cancer participating in the
EPIC (European Prospective Investigation into Cancer
and Nutrition) cohort. Importantly, the authors
showed that higher pre-diagnosis circulating OPG
concentrations - assessed by an electrochemilumines-
cent assay - are associated with a greater risk of breast
cancer-specific and overall mortality, especially in
ER-positive breast cancer patients [137]. Similarly,
Rachner et al. showed that higher OPG serum levels -
detected by ELISA - are associated with a significantly
higher risk of death from breast cancer in patients with
primary, non-metastatic breast cancer. Furthermore,
the authors also reported that OPG represents an inde-
pendent prognostic marker for breast cancer specific
survival on multivariate analyses [138]. Nonetheless,
these data are in sharp contrast with another study
conducted on a large microarray dataset of primary
breast cancer patients, which reported that high OPG
mRNA levels correlate with longer overall and
disease-free survival [139]. Park et al. showed that
OPG is not a valuable prognostic factor on multivari-
ate analysis for skeletal-disease free survival, disease-
free survival and overall survival in a study based on
the analysis of tissue microarrays obtained from 185
patients with primary breast cancer. The authors also
found that OPG expression correlates with more favor-
able tumor clinical and pathologic features, including
small tumor size, negative lymph node involvement,
and low proliferative index [78]. Overall, these conflict-
ing findings may be related to the diverging effects of
OPG expression according to distinct breast cancer
subtypes [31] and/or to different methods used for
OPG expression analysis in different studies (e.g. quan-
titative PCR, immunohistochemistry). According to the
recent findings from Sarink et al. [137] and Rachner et
al. [138], it is also possible that OPG circulating con-
centrations at diagnosis represent a more informative
measure for breast cancer prognosis and mortality
than OPG expression in tumor tissue. Further investi-
gations in well-defined patient cohorts (e.g. according
to tumor characteristics) are needed to confirm these
findings.
Finally, OPG produced by breast cancer cells appears
to contribute to tumor growth and progression at the
primary tumor site, while acting as a protective factor
in bone microenvironment by preventing breast
cancer-induced bone loss and reducing intra-osseous
tumor growth. Nevertheless, most of these data derive
from observations in vitro and further studies are war-
ranted to confirm whether OPG exerts the same ef-
fects in vivo.
Influence of RANKL/RANK/OPG system on bone
metastasis in breast cancer
Breast cancer represents a neoplasm with high propen-
sity to spread to bone; in fact, about 70% of patients
with advanced breast cancer develop bone metastases
[140]. Of note, skeletal invasion of breast cancer cells is
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usually associated with osteolytic lesions [141], which
lead to sustained bone resorption and skeletal-related
events (SREs), defined as pathological fractures, hyper-
calcemia, spinal cord compression, or bone pain [142].
RANKL/RANK/OPG system may have an important
role in promoting migration of breast cancer cells to
the bone and their subsequent metastatic behavior [23,
24, 26, 135, 143]. In fact, RANKL has been reported to
accelerate the migration and metastasis of RANK-ex-
pressing cancer cells [24]. High levels of RANK in
tumor specimens from patients with primary breast
cancer have been correlated with poor prognosis,
higher risk to develop bone metastases, and shorter
skeletal disease-free survival [139]. Moreover, an high
concordance in RANK expression between bone metas-
tasis and corresponding breast primary tumor has been
also reported [77]. A recent retrospective analysis on a
cohort of 509 patients with primary, non-metastatic
breast cancer (median follow-up: 8.50 years; median age
of participants: 60 years) found that RANKL serum
levels were significantly higher in patients with dissemi-
nated tumor cells in the bone marrow, as well as in pa-
tients who developed bone metastases. Moreover,
patients within the highest quartile of RANKL showed
a significantly increased risk of developing bone metas-
tases compared to those in the lowest quartile [138].
The exact role of OPG within the bone metastatic
niche in breast cancer still remains controversial [31,
122, 124, 135, 144–146]. Neville-Webbe et al. showed
that bone marrow stromal cells isolated from breast can-
cer patients are able to produce OPG at levels that are
sufficient to protect breast cancer cells from TRAIL-in-
duced apoptosis, supporting a role of bone-derived OPG
in promoting survival of breast cancer cells within the
bone metastatic niche [144]. However, Ottewell et al.
found that recombinant OPG markedly counteracts
growth of dormant MDA-MB-231 cells at the skeletal
level in a murine model of disseminated breast cancer
cells, thus preventing development of bone metastases
[122]. Chanda et al. investigated the effects of sustained
OPG-Fc expression using a recombinant adeno-associated
viral vector in a mouse model of osteolytic breast cancer,
finding a significant reduction in skeletal tumor growth
and bone loss, despite no effects on long-term survival
[145]. Moreover, a conditionally replicating adenovirus
(CRAd) characterized by a shortened OPG-Fc reduced
tumor burden in the bone and osteoclast formation more
effectively than an unarmed CRAd in a murine model of
osteolytic bone metastases of breast cancer [146].
As cancer cells home to bone, favorable interactions
between these cells and bone microenvironment are es-
sential for the initiation of osteolytic metastasis, ac-
cording to the “seed and soil” hypothesis [147]. In this
context, impaired regulation of RANKL/RANK/OPG
system and excessive osteoclast-induced bone resorp-
tion have been shown to play an important role in pro-
moting bone metastasis in certain malignant diseases,
including breast cancer [148]. Breast tumor cells can
secrete PTHrP and other soluble mediators (e.g.
TNF-α, IL-1, IL-6, IL-8, M-CSF) able to promote osteo-
clastogenesis and osteolytic lesions through RANKL
upregulation by osteoblasts and stromal cells [149,
150]. PTHrP can also decrease OPG levels from osteo-
blasts [151], further upregulating RANKL-to-OPG ratio
in skeletal metastases [44]. Therefore, osteoclastic re-
sorption gives rise to increased release of TGF-β (trans-
forming growth factor-β) and other soluble factors
from the bone matrix, which promote increased prolif-
eration of cancer cells and enhance PTHrP production
[150, 152]. In turn, PTHrP stimulates osteoblasts and
stromal cells to secrete RANKL, which drives osteoclast
activation and further release of TGF-β from the bone
[150, 151]. The complex cross-talk between breast can-
cer cells and bone microenvironment is thereby respon-
sible for a detrimental “vicious cycle”, which ultimately
favors metastatic tumor promotion, progression and
bone destruction, with the establishment of de novo
bone metastasis and severe clinical morbidities [44].
Therapeutic perspectives in humans: targeting
RANKL/RANK/OPG system for prevention and
treatment of breast cancer
As previously discussed, RANKL accelerates the migra-
tion and metastasis of RANK-expressing cancer cells
[24] and acts as the final effector of osteoclastogenesis in
the vicious cycle of bone destruction in metastatic bone
disease [150]. Thus, inhibition of RANKL may poten-
tially counteract migration of RANK-positive cancer
cells and make the bone less attractive for these cells,
preventing and reducing tumor outgrowth in the skel-
eton. This phenomenon could rely, at least in part, on
the fact that inhibition of RANKL is able to curb the dir-
ect effect of RANKL on RANK-expressing cancer cells
[23, 86]. In humans, inhibition of RANKL/RANK system
can be obtained from the use of the human monoclonal
antibody denosumab, that specifically inhibits RANKL
and blocks its binding to RANK. Denosumab is cur-
rently used in clinical settings for the treatment of
women at high risk for bone fractures, such as postmen-
opausal women with osteoporosis and patients with
non-metastastic breast cancer on aromatase inhibitors
therapy [153, 154]. High dose denosumab (120 mg every
4 weeks) has recently become a standard of care, in
addition to chemotherapy, in patients with bone meta-
static breast cancer [155], where it has been shown super-
ior to bisphosphonates in delaying or preventing SREs
[142, 156–158]. The difference between denosumab and
bisphosphonates in SREs prevention may depend on the
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distinct mechanisms of action of the two agents. In fact,
bisphosphonates act only on mature and active osteo-
clasts, whereas inhibition of RANKL prevents survival, ac-
tivation and differentiation of osteoclasts from their
precursor cells, leading to a total lack of osteoclasts in
treated bone [159]. However, no significant differences in
overall survival have been observed among patients with
bone metastatic breast cancer receiving either denosumab
or zoledronate [156].
In agreement with pre-clinical findings [23, 46], accu-
mulating evidence highlights RANKL/RANK pathway as
a potential therapeutic target not only in bone metastasis
management, but even in breast cancer prevention and
adjuvant clinical settings [86]. In fact, ongoing clinical
trials are evaluating if denosumab is able to prevent the
development of bone metastasis and disease recurrence
in the adjuvant phase of breast cancer treatment [86].
Early promising data have been shown from the
ABCSG-18 study, an ongoing randomized phase III trial
recruiting postmenopausal women with early-phase hor-
mone receptor-positive breast cancer treated with aroma-
tase inhibitors as adjuvant therapy and randomly assigned
to receive either placebo or denosumab 60mg every 6
months (ClinicalTrials.gov identifier: NCT00556374). Pa-
tients receiving denosumab have shown a significant de-
layed time to first clinical fracture (primary endpoint of
the study) compared with placebo group. Importantly, re-
duction in fracture risk was irrespective of age and base-
line bone mineral density [160]. According to current
evidence, zoledronate or six monthly denosumab for the
entire duration of aromatase inhibitors therapy represents
the standard of care in postmenopausal women receiving
aromatase inhibitors, aimed at preventing bone loss asso-
ciated with the adjuvant hormonal therapy. Of note, deno-
sumab is recommended when fracture prevention is the
priority, whereas zoledronate when breast cancer recur-
rence is the major concern [154]. To date, adjuvant bis-
phosphonate treatment in breast cancer has been found to
reduce disease recurrence and improve disease-free sur-
vival and overall survival only in postmenopausal settings
[157, 161]. However, there is still a lack of knowledge
about the different impact of bisphosphonates and deno-
sumab on disease recurrence and overall survival among
patients with early and advanced non-metastatic breast
cancer. Preliminary results from ABCSG-18 suggest a sig-
nificant improvement in disease-free survival among pa-
tients receiving denosumab with respect to placebo group
after 5 and 8 years of follow-up [160, 162]. As a conse-
quence, denosumab may be offered to all postmenopausal
women with hormone receptor-positive breast cancer on
aromatase inhibitors, not only for aromatase inhibitor-as-
sociated bone loss and bone fractures prevention, but even
for adjuvant purposes, including improvement in
disease-free survival [163]. However, these promising
results are in contrast with those observed in the D-CARE
trial (ClinicalTrials.gov identifier: NCT01077154), a ran-
domized phase III placebo-controlled study which has
been recently terminated. D-CARE trial had the primary
objective to evaluate whether 5-year denosumab adminis-
tration (at higher doses compared with those used in the
ABCSG-18 study, namely: 120mg every 4 weeks for 6
months, then 120mg every 3months) is superior to pla-
cebo in improving disease-specific outcomes (bone-metas-
tasis free survival, disease-free survival and overall
survival) in women with early-stage breast cancer receiv-
ing optimal loco-regional and standard of care systemic
(neo)adjuvant therapy. After a median follow-up of 67
months, denosumab showed improvement in time to
bone metastasis as first recurrence, but it did not improve
bone-metastasis free survival, disease-free survival and
overall survival in all the study groups (including the sub-
set of postmenopausal patients) [164]. These opposing re-
sults may be partly explained by the different features of
the subjects recruited in D-CARE and ABCSG-18 trials.
In fact, D-CARE study enrolled a more heterogeneous
population, consisting of both pre- and postmenopausal
breast cancer patients. Noteworthy, patients in D-CARE
trial were also at high risk of disease recurrence, as defined
by lymph node-positive disease (assessed by biopsy evalu-
ation) and/or tumor size > 5 cm (T3) or locally advanced
disease (T4). On the other hand, ABCSG-18 trial has re-
cruited only postmenopausal women with histologically
confirmed non-metastatic hormone receptor-positive
breast cancer receiving treatment with adjuvant aromatase
inhibitors [160, 162]. Therefore, long-term data from
ABCSG-18 study will be helpful to further assess the ef-
fects of denosumab on additional outcomes, such as
bone-metastasis free survival and overall survival.
Moreover, clinical trials are deemed necessary to
evaluate disease recurrence and overall survival in pre-
and postmenopausal women with early hormone sensi-
tive breast cancer on adjuvant hormonal therapy (tam-
oxifen, aromatase inhibitors) receiving either denosumab
or zoledronate to prevent cancer treatment-induced
bone loss. Additional data on the role of denosumab as
a potential anti-tumor agent in breast cancer are ex-
pected from PERIDENO (ClinicalTrials.gov identifier:
NCT03532087), a prospective randomized phase II study
investigating the impact of (neo)adjuvant denosumab on
systemic immunity and local immune microenvironment
in postmenopausal patients with early breast cancer. It is
also important to note that RANK expression has been
found in a subset of TNBCs [82]. With this regard, an
upcoming randomized phase II neoadjuvant clinical trial
(GeparX, ClinicalTrials.gov identifier: NCT02682693) is
recruiting patients with hormone receptor-negative
primary breast cancer in order to assess whether admin-
istration of denosumab (120 mg every 4 weeks for 6
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cycles) as an add-on neoadjuvant treatment is able to in-
crease pathological complete response rate and improve
outcome in relation to RANK tumor expression.
As previously mentioned, pre-clinical studies have
shown that denosumab reduces mammary epithelial and
progenitor cells proliferation in patients with BRCA1
mutation [28, 29, 165]. Therefore, pharmacological in-
hibition of RANKL may be also considered as a novel,
promising targeted approach in BRCA1 mutation car-
riers, aimed at preventing breast cancer initiation. In
particular, large randomized clinical trials on BRCA1
mutation carriers are needed to ascertain if denosumab
is able to reduce breast cancer risk when associated with
active surveillance in primary prevention. In this con-
text, denosumab could be considered as a useful thera-
peutic strategy in premenopausal settings, aimed at
delaying the need for bilateral prophylactic mastectomy
and counteracting the bone loss after bilateral prophy-
lactic salpingo-oophorectomy. With this regard, the pilot
study BRCA-D (Trial ID: ACTRN12614000694617) is
recruiting pre-menopausal women carrying a BRCA1 or
BRCA2 mutation to establish if denosumab (120mg
monthly for 3 months) affects proliferation - assessed by
Ki67 expression - in the breast epithelium of such indi-
viduals. Since RANK expression has been detected in a
relevant proportion of cancers arising in BRCA1 muta-
tion carriers [79], it will be also critical to investigate if
RANKL inhibition can abrogate breast cancer progres-
sion at the early stages of tumorigenesis and/or if it of-
fers significant advantages as add-on treatment option to
adjuvant hormonal therapy in reducing the risk for
contralateral breast cancer [166]. It is worth to note that
RANKL expression is markedly upregulated in postmen-
opausal women, resulting in augmented bone resorption
and increased risk for osteoporosis [167]. In turn,
RANKL upregulation in bone microenvironment may
play direct effects on RANK-expressing breast cancer
cells. In light of these data, RANKL inhibition may be
potentially beneficial especially for postmenopausal
women, including those carrying BRCA1 mutation.
In conclusion, the therapeutic potential of targeting
OPG is still under debate. Indeed, the therapeutic use of
recombinant OPG for prevention of bone metastasis in
breast cancer is currently strongly limited by the lack of
knowledge on the exact role of OPG in human breast
tumorigenesis. Importantly, OPG can no longer be con-
sidered as a factor acting solely within the bone micro-
environment in breast cancer. Hence, caution should be
used in the development of systemic therapies aimed at
increasing OPG levels in patients with breast cancer.
Moreover, the beneficial effects showed by denosumab
in delaying or preventing SREs in bone metastatic breast
cancer [142, 156–158] is likely to have overwhelmed the
clinical research on the use of recombinant OPG for
prevention of osteolysis associated with metastatic bone
disease, as well as for prevention of bone metastatic dis-
ease itself. In fact, the therapeutic use of OPG in breast
cancer has no longer been studied, since the phase I
study evaluating the skeletal effects of the AMGN-0007
compound has been interrupted [117]. In light of our
current knowledge, we believe that the use of recombin-
ant OPG in the future may be limited to patients with
bone metastatic breast cancer, which could benefit from
its administration in terms of morbidity and mortality.
However, future studies are needed to evaluate the real
feasibility and efficacy of therapeutic strategies for local-
ized delivery of OPG to the bone (e.g. gene therapy),
aimed at inhibiting osteolysis and bone loss in patients
with bone metastatic breast cancer.
Concluding remarks and future directions
A growing body of evidence points toward a critical in-
volvement of RANKL/RANK pathway in breast cancer
initiation and progression through different mechanisms,
such as increased proliferation and survival of mammary
epithelial cells, enhanced MaSCs expansion, and induc-
tion of EMT. At a molecular level, expression of RANKL
and RANK within mammary gland is mainly regulated
by progesterone. Thus, RANKL/RANK system may rep-
resent one of the key factors linking progesterone and
progestins to increased breast cancer risk in women.
However, the existence of hormone-independent mecha-
nisms controlling mammary RANKL and RANK expres-
sion has also been postulated. RANKL and RANK
expression has been documented in different human
breast cancers subtypes, including hormone receptor-
positive cancers, TNBCs and BRCA-deficient cancers.
Moreover, RANKL- and/or RANK-positive breast can-
cers have been associated with a poor prognosis in
different clinical studies. To date, targeting RANKL rep-
resents a valid therapeutic approach to prevent and
manage SREs in the context of bone metastatic breast
cancer. Furthermore, a series of pre-clinical studies dem-
onstrated that RANKL inhibition reduces proliferation
of mammary epithelial cells and MaSCs, besides attenuat-
ing the occurrence of pre-neoplastic lesions and mam-
mary tumors. Based on pre-clinical findings, RANKL
inhibition may play also a central role in prevention of dis-
ease recurrence and bone metastases in the context of
established breast cancer. Nonetheless, whether denosu-
mab may have a place in breast cancer prevention and
treatment among the subpopulation of RANK-expressing
early breast cancer patients is still an open question. It will
be also important to evaluate if a large spectrum of
breast cancer patients may benefit from denosumab, or
if its use is substantially limited to specific age and/or
breast cancer subtypes.
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Overall, results from ongoing studies and future large
randomized clinical trials are awaited to assess the
potential use of denosumab as an anti-tumor agent in
different breast cancer settings, namely: a) as a disease-
modifying agent in hormone receptor-positive breast
cancer patients on adjuvant hormonal therapy, which
would be beneficial even for prevention of cancer
treatment-induced bone loss, b) as a disease-modifying
agent in patients with TNBC and ErbB2-positive breast
cancer, c) as an add-on adjuvant therapy in BRCA1 mu-
tation carriers for the treatment of established breast
cancer and/or prevention of contralateral breast cancer,
d) as a novel chemoprevention approach in BRCA1
mutation carriers, aimed at reducing breast cancer risk,
delaying the need for bilateral prophylactic mastectomy
and counteracting the prophylactic oophorectomy-in-
duced bone loss. As extensively discussed, RANKL/
RANK system is a key paracrine effector of progester-
one signaling on breast epithelium and repeated prolif-
erative cell response elicited by progesterone-RANKL
axis can represent a risk factor for breast cancer. In this
context, young premenopausal women with high risk
for breast cancer may become a potential target group
to study the effectiveness of denosumab in preventing
breast cancer.
Finally, data on the exact role of OPG in tumorigenesis
and metastatic process, as well as its prognostic value in
human breast cancer are still under debate. According to
pre-clinical findings, effects of OPG in breast cancer ap-
pear to vary depending on its site of action. Indeed, inter-
action of OPG with breast cancer cells can lead to tumor
growth and progression through different mechanisms.
However, in vitro and in vivo studies on the role of OPG
in breast tumorigenesis are controversial: in fact, in vitro
studies suggest a role of OPG in promoting primary
tumor growth and progression, whereas there is a lack of
effect in vivo. These conflicting findings may depend on
the complex interactions between OPG, TRAIL and
RANKL in vivo. On the other hand, most pre-clinical
studies suggest a protective role of OPG against tumor
growth and osteolysis within the bone metastatic niche in
breast cancer. Nonetheless, caution should be taken in
translating pre-clinical findings on the role of OPG in
breast tumorigenesis to humans, as well as in develop-
ment of systemic therapeutic strategies aimed at increas-
ing OPG levels in patients with bone metastatic breast
cancer. Therefore, future studies are required to better
elucidate the role of OPG in breast cancer initiation and
progression in vivo, and to subsequently investigate the
potential efficacy of therapeutic strategies targeting OPG
in different breast cancer settings.
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